Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.34 |
| ▸ | MEN1 | O00255 | 2/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | SGMS2 | Q8NHU3 | 1/20 | 0.33 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.33 |
| ▸ | LTA4H | P09960 | 2/20 | 0.33 |
| ▸ | PTGER1 | P34995 | 2/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.33 |
| ▸ | HTR2C | P28335 | 1/20 | 0.33 |
| ▸ | HTR2B | P41595 | 1/20 | 0.33 |
| ▸ | RORC | P51449 | 1/20 | 0.33 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6596294 | 0.85 | PTGER1 (0.39) | ALDH1A1MEN1KMT2ASGMS2PRMT5 | |
| SCHEMBL6081001 | 0.79 | MEN1 (0.36) | ALDH1A1MEN1KMT2ASGMS2PTGER1 | |
| SCHEMBL6080659 | 0.77 | PTGER1 (0.44) | PTGER1 | |
| SCHEMBL6079943 | 0.74 | PTGER1 (0.41) | PTGER1 | |
| SCHEMBL6080002 | 0.74 | MAP4K4 (0.43) | PTGER1 | |
| SCHEMBL6079219 | 0.74 | ERN1 (0.48) | ALDH1A1PTGER1SRD5A2 | |
| SCHEMBL6080257 | 0.73 | PTGER1 (0.41) | MEN1KMT2APTGER1 | |
| SCHEMBL6080066 | 0.72 | PTGER1 (0.43) | PTGER1 | |
| SCHEMBL6080053 | 0.71 | MMP2 (0.39) | ALDH1A1MEN1KMT2APTGER1SRD5A2 | |
| SCHEMBL6080030 | 0.68 | PTGER1 (0.41) | ALDH1A1PTGER1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060183909-A1 | Compositions derived from quinoline and quinoxaline, preparation and use thereof | NEURO3D (FR) | 2006-08-17 | — | — | US | claimed |
| US-20060183909-A1 | Compositions derived from quinoline and quinoxaline, preparation and use thereof | NEURO3D (FR) | 2006-08-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060183909-A1 | Compositions derived from quinoline and quinoxaline, preparation and use thereof | NQO1, NQO2, RECQL | ALDH1A1 2726/4885MEN1 740/4885KMT2A 1384/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.